These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24517233)

  • 1. Genetic variants of drug metabolizing enzymes and drug transporter (ABCB1) as possible biomarkers for adverse drug reactions in an HIV/AIDS cohort in Zimbabwe.
    Dhoro M; Ngara B; Kadzirange G; Nhachi C; Masimirembwa C
    Curr HIV Res; 2013 Sep; 11(6):481-90. PubMed ID: 24517233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
    Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
    Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
    Masebe TM; Bessong PO; Nwobegahay J; Ndip RN; Meyer D
    Dis Markers; 2012; 32(1):43-50. PubMed ID: 22297601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
    Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
    Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
    Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
    Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
    Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
    Micheli JE; Chinn LW; Shugarts SB; Patel A; Martin JN; Bangsberg DR; Kroetz DL
    Pharmacogenet Genomics; 2013 Nov; 23(11):591-6. PubMed ID: 23982262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.
    Kim SH; Kim SH; Yoon HJ; Shin DH; Park SS; Kim YS; Park JS; Jee YK
    Eur J Clin Pharmacol; 2011 Feb; 67(2):121-7. PubMed ID: 20941486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort.
    Zhu P; Zhu Q; Zhang Y; Ma X; Li Z; Li J; Chen J; Luo L; Ring HZ; Ring BZ; Su L
    PLoS One; 2013; 8(1):e55197. PubMed ID: 23372834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
    Saitoh A; Capparelli E; Aweeka F; Sarles E; Singh KK; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    J Acquir Immune Defic Syndr; 2010 Jul; 54(3):285-9. PubMed ID: 19890215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
    Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
    Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis.
    Kim SH; Kim SH; Bahn JW; Kim YK; Chang YS; Shin ES; Kim YS; Park JS; Kim BH; Jang IJ; Song J; Kim SH; Park HS; Min KU; Jee YK
    Pharmacogenomics; 2009 Nov; 10(11):1767-79. PubMed ID: 19891553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.